RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FAVALLI EG
Collezione AO Ordine Mauriziano

Items : 6

Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. in Autoimmunity reviews / Autoimmun Rev. 2020 May;19(5):102509. doi: 10.1016/j.autrev.2020.102509. Epub 2020 Mar 12.

2020
AO Ordine Mauriziano

Bodio C; Grossi C; Pregnolato F; Favalli EG; Biggioggero M; Marchesoni A; Murgo A; Filippini M; Migliorini P; Caporali R; Pellerito R; Ciccia F; Sarzi-Puttini P; Perosa F; Paolazzi G; Hollan I; Bendtzen K; Meroni PL; Borghi MO;

Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. in International journal of rheumatic diseases / Int J Rheum Dis. 2018 Feb;21(2):422-430. doi: 10.1111/1756-185X.13199. Epub 2017 Oct 30.

2018
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pellerito R; Sarzi Puttini PC; Fusaro E; Atzeni F; Bazzani C; Grosso V; Gorla R; Becciolini A; Caporali R; Sinigaglia L; Favalli EG;

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. in Clinical and experimental rheumatology / Clin Exp Rheumatol. 2017 Sep-Oct;35(5):804-809. Epub 2017 Jul 27.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Pellerito R; Fusaro E; Bazzani C; Gorla R; Sarzi Puttini P; Atzeni F; Grosso V; Favalli EG; Caporali R; Manara M; Rocchetta PA; Sinigaglia L;

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. in Clinical and experimental rheumatology / Clin Exp Rheumatol. 2017 Jul-Aug;35(4):660-665. Epub 2017 May 8.

2017
AO Ordine Mauriziano

Codullo V; Iannone F; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Ferraccioli G; Gremese E; Carletto A; Giollo A; Govoni M; Bergossi F; Galeazzi M; Cantarini L; Salaffi F; Di Carlo M; Bazzani C; Pellerito R; Sebastiani M; Ramonda R; Lapadula G; Caporali R;

Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. in Clinical rheumatology / Clin Rheumatol. 2017 Apr;36(4):753-761. doi: 10.1007/s10067-016-3528-y. Epub 2017 Jan 5.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Favalli EG; Marchesoni A; Rocchetta PA; Paolazzi G; Fusaro E; Atzeni F; Pellerito R; Gorla R; Sarzi-Puttini P; Klersy C; Monti S; Caporali R;

Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. in Clinical rheumatology / Clin Rheumatol. 2016 Nov;35(11):2649-2656. doi: 10.1007/s10067-016-3349-z. Epub 2016 Jul 14.

2016
AO Ordine Mauriziano

Iannone F; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Caporali R; Codullo V; Ferraccioli G; Gremese E; Carletto A; Giollo A; Govoni M; Bergossi F; Galeazzi M; Cantarini L; Salaffi F; Di Carlo M; Bazzani C; Pellerito R; Sebastiani M; Ramonda R; Lapadula G;